Corticosteroids have been a constant in immunosuppressive regimens since the beginning of solid organ transplantation. Although the use of corticosteroids allowed the advancement of transplantation in the early years, this came at the price of numerous adverse events for patients. As the survival of transplanted organs has risen over the past several years, increasing attention has been focused on the management of long-term complications. Many of these long-term complications are directly related to the toxicities of immunosuppressiveagents. Due to these toxicities, we have seen a resurgence in immunosuppressive protocols that utilize regimens designed to minimize these long-term complications. This has been accomplished by avoiding, reducing or withdrawing one or more medications from the multi-drug regimens. Corticosteroids, with their plethora of side affects, have been of major interest to the transplant community in terms of minimizing side affects by limiting exposure.
Get full access to this article
View all access options for this article.
References
1.
1. Cohen D. Action, efficacy, and toxicities: corticosteroids. In: NormanD, Turka L, eds. Primer on Transplantation. 2nd ed. Mt. Laurel, NJ: American Society of Transplantation; 2001:146-151.
2.
2. Danovitch G. Immunosuppressive medications and protocols for kidney transplantation. In: Danovitch G, ed. Handbook of Kidney Transplantation. 3rd ed. LippincottWilliams & Wilkins; 2000: 62-110.
3.
3. Fauci AS. The effect of hydrocortisone on the kinetics of normal humanlymphocytes. Blood. 1975;46:235-240.
4.
4. AlmawiWy, Hadro ET, Strom TB. Evidence that glucocorticoidmediated immunosuppressive effects do not involve altering second messenger function. Transplantation. 1991;52:133-140.
5.
5. Vacca A, Felli MP, Farina AR, et al. Glucocorticoid receptormediated suppressionof the interleukin2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Ex p Med. 1992;175: 637-646.
6.
6. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci. 1993;14:436-441.
7.
7. Barnes PJ, Karin M. Nuclear factor kappa-beta—a pivotal transcriptionfactor inchron ic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
8.
8. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF kappa beta and the glucocorticoid receptor. Proc Natl Acad Sci USA. 1994;91:752-756.
9.
9. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activationof kappa beta inmediationof immunosuppressionby glucocorticoids. Science. 1995;270:283-286.
10.
10. Granelli-Piperno A, Nolan P, Inaba K, et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites in the interleukin 2 promoter. J ExpMed. 1990;172: 1869-1872.
11.
11. Hricik DE. Steroid-free immunosuppression in kidney transplantation: an editorial review. Am J Transplant. 2002;2:19-24.
12.
12. Alloway R, Holt C, Somerville KT. Solid organ transplant. In: Module 7 Nephrology and Immunology—Pharmacotherapy Self-Assessment Program. 3rd ed. Kansas City, Mo: American College of Clinical Pharmacy; 1999:219-272.
14. Dupont E, Schandene L, Nenys C, et al. Differential in-vitro actions of cyclosporine, methyl-prednisolone, and 6-mercaptopurine: implication for drugs influence on lymphocyte activationmechan isms. Clin Immunol Immunopathol. 1986;40:422-422.
15.
15. Hussey JL. Discontinuance of immuno-suppression [letter]. Arch Surg. 1976;111:614-614.
16.
16. BrownM W, Forwell MA. Rejectionreactionafter stopping prednisolone in kidney transplant recipients taking cyclosporine. N Engl J Med. 1986;314:183-183.
17.
17. Cristinelli L, Brunori G, Setti G, et al. Withdrawal of methylprednisolone at the sixth month in renal transplant recipients treated with cyclosporine. Transplant Proc. 1987;19:2021-2023.
18.
18. Matas A, ThiagarajanR, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant. 2001;1:278-283.
19.
19. Williams GH, Dluhy RG. Disease of the adrenal cortex. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 1998:2035-2035.
20.
20. Veenstra DL, Best JH, Hornberger J, et al. The incidence and longterm cost of steroid-related side effects after renal transplantation. Am J Kidney Dis. 1999;33:829-839.
21.
21. Criterio F. Steroid side effects and their impact on transplantationoutcome. Transplantation. 2001;72:SS75-SS79.
22.
22. US Renal Data System. USRDS 2000 Annual Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 2000.
23.
23. Tejani A, Fine R, Alexander S, et al. Factors predictive of sustained growth in children after renal transplantation. J Pediatr. 1993;122:397-402.
24.
24. TejaniA, Sullivan K. Long-term follow-up of growth in children post-transplantation. Kidney Int. 1993;44(suppl 43):S56-S58.
25.
25. TejaniA, Cortes L, Sullivan EK. Alongitudinal study of the natural history of growth post-transplantation. Kidney Int. 1996; 49(suppl 53):S103-S108.
26.
26. Jabs K, SullevanEK, Avner ED, et al. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. Transplantation. 1996;61:31-36.
27.
27. Hardie IR, Matsunami C, Hilton A, et al. Ocular complications in renal transplant recipients. Transplant Proc. 1992;24:177-179.
28.
28. Pai RP, Mitchell P, Chow VC, et al. Post-transplant cataract: lessons from kidney-pancreas transplantation. Transplantation. 2000;69:1108-1114.
29.
29. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med. 1998;104:459-459.
31. Horber FF, Casez Jp, Steiger U, et al. Changes in bonemass early after kidney transplantation. J Bone Miner Res. 1994;9:1-9.
32.
32. Wolpaw T, Deal CL, Fleming-Brooks S, et al. Factors influencing vertebral bone density after renal transplantation. Transplantation. 1994;58:1186-1189.
33.
33. Sinclair NRS. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Can Med Assoc J. 1992;147:645-657.
34.
34. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res. 1996;11:1-7.
35.
35. Jindal RM, Sidner RA, Milgrom ML. Post transplant diabetes mellitus: the role of immunosuppression. Drug Safety. 1997; 16(4):242-257.
37. Fellstrom B. Impact and management of hyperlipidemia posttransplant. Transplantation. 2000;70(11 suppl):SS51-SS51.
38.
38. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1989;48:37-37.
39.
39. Hricik DE, Bartucci MR, Mayer JT, et al. The effects of steroid withdrawal onthe lipoproteinprofiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation. 1992;54:868-868.
41. Starzl TE, Marchioro TL, Rifkind D, et al. Factors in successful renal transplantation. Surgery. 1964;56:296-296.
42.
42. McGeown MG, Kennedy JA, LoughridgeW, et al. One hundred kidney transplants in the Belfast city hospital. Lancet. 1977;2: 648-651.
43.
43. McGeownM G, Douglas JF, BrownWA, et al. Advantages of lowdose steroid from the day after renal transplantation. Transplantation. 1980;29:287-289.
44.
44. ChanL, FrenchME, Beare J, et al. Prospective trial of high-dose steroids versus low-dose prednisolone in renal transplant patients. Transplant Proc. 1980;29:287-289.
45.
45. Chan L, French ME, Oliver DO, et al. High- and low-dose prednisolone. Transplant Proc. 1981;13:336-338.
46.
46. Morris PF, Chan L, FrenchME, et al. Low-dose oral prednisolone in renal transplantation. Lancet. 1982;1:525-527.
47.
47. Hricik DE, Almawi WY, Ttrom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation. 1994;57: 979-989.
48.
48. d’Apice AJF, Becker GJ, Kincaid-Smith P, et al. A prospective randomized trial of low-dose versus high-dose steroid in cadaveric renal transplantation. Transplantation. 1984;37(4):373-377.
49.
49. Walker RG, d’Alpice AJF, Mathew TH, et al. Long-term followup of a prospective trial of low-dose versus high-dose steroids in renal transplantation. Transplant Proc. 1987;19:2825-2828.
50.
50. Walker RG, d’Apice AJF. Non-specific immunosuppression: azathioprine and steroids. In: Morris PJ, ed.Kidney Transplantation: Principles and Practices. 4th ed. Philadelphia: W. B. Saunders; 1984:202-204.
51.
51. Immunosuppression. In: Stuart F, AbecassisM, Kaufman D, eds. Organ Transplantation. Georgetown, Tex: Landes Bioscience; 2000:45-56.
52.
52. Canafax CM, Sutherland DER, Simmons RL, et al. Combination immunosuppression: three drugs (azathioprine, cyclosporine, prednisolone) for mismatched related and four drugs (antilymphocyte globulin, azathioprine, cyclosporine, prednisolone) for cadaver renal allograft recipients. Transplant Proc. 1985; 17:2671-2672.
53.
53. Hiesse C, Charpentier B, Fries D. Safety of triple immunosuppressive treatment (cyclosporine, azathioprine and prednisolone). Lancet. 1985;2:1355-1355.
54.
54. Kassiske BL. Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol. 2000;11:1910-1917.
55.
55. Hricik DE, O’TooleMA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol. 1993;4:1300-1305.
56.
56. Vanrenerghem Y, Lebranchu Y, Hene R, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil—a prospective randomized study. Transplantation. 2000;70:1352-1370.
57.
57. Hricik DE, Seliga RM, Fleming-Brooks S, et al. Determinants of long-term allograft function following steroid withdrawal in renal transplant recipients. Clin Transplant. 1995;9:419-423.
58.
58. Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil—a prospective randomized study.Transplantation. 1999;68:1865-1874.
59.
59. Vincenti F, Monaco A, Grinyo J, et al. Rapid steroid withdrawal versus standard treatment in patients treated with Simulect, Neoral, and CellCept for the preventionof acute rejectioninre --nal transplantation: a multicenter, randomized trial. Transplantation. 2000;69(suppl):S133-S133.
60.
60. Cole EH, Landsberg DN, Russell D, et al. Apilot study of steroidfree immunosuppressioninthe preventionof acute rejectionin renal allograft recipients. Transplantation. 2001;72:845-850.
61.
61. Matas A, ThiagarajanR, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant. 2001;1:278-283.
